See also:
		 
			
				
					All hypertension clinical trials
				
			
		
			
			All clinical trials of strategy 
			
		
		
			
			All clinical trials of more intensive blood pressure lowering strategie 
			
		
	 | 
	
		 
	 | 
	
		
	Treatments
	
	
		| Studied treatment | 
		
		intensive treatment (diastolic blood pressure decrease
of 10 mmHg below baseline DBP)
		 
		
		
		 | 
	 
	
		| Control treatment | 
		
		moderate treatment (diastolic blood pressure goal of 80-89 mmHg)
		 
		
		
		 | 
	 
		
			| Remarks | 
			patients randomized to intensive therapy received either nisoldipine or enalapril in a blinded
manner as the initial antihypertensive medication | 
		 
			| Treatments description  | 
				
				
						
						| Achieved systolic blood | 
						128/137  | 
						 
						
						| Achieved diastolic blood pressure | 
						75/81  | 
						 
				 	
				 | 
			 
	 
	
	
	
	Patients
	
		
			| Patients | 
			diabetes patients with diastolic
blood pressure between 80 and 89mmHg | 
		 
	 
	
	
	
	
	
	
	Method and design
	
	
		| Randomized effectives | 
		237 / 243 (studied vs. control) | 
	 
		
			| Design | 
			Parallel groups | 
		 
		
			| Blinding | 
			open | 
		 
	
	 
	
	
	
	
	
	
	
  
	Results	
	
	
	
		
	
	
		
			Endpoint
		
	
	
		
		Studied treat. n/N
			
	
	
		
		Control treat. n/N
		
	
	
		
			Graph
		
	
	
		
			RR [95% CI]
		
	
	
		
			
				
				Cardiovascular death
				 
			
		
			
				
				13 / 237 
				
			
			
				
				9 / 243 
				
			
		
			
				
					
						classic
					
					
					
				
			
				
				
			
			
		
			
				
					1,48 [0,65;3,40]
				
			
	
	
		
			
				
				myocardial  infarction (fatal and non fatal) 
				 
			
		
			
				
				19 / 237 
				
			
			
				
				15 / 243 
				
			
		
			
				
					
						classic
					
					
					
				
			
				
				
			
			
		
			
				
					1,30 [0,68;2,50]
				
			
	
	
		
			
				
				Heart failure
				 
			
		
			
				
				12 / 237 
				
			
			
				
				11 / 243 
				
			
		
			
				
					
						classic
					
					
					
				
			
				
				
			
			
		
			
				
					1,12 [0,50;2,49]
				
			
	
	
		
			
				
				All cause death
				 
			
		
			
				
				18 / 237 
				
			
			
				
				20 / 243 
				
			
		
			
				
					
					
					
					
				
			
				
				
			
			
		
			
				
					0,92 [0,50;1,70]
				
			
	
	
		
			
				
				non cardiovascular death 
				 
			
		
			
				
				5 / 237 
				
			
			
				
				11 / 243 
				
			
		
			
				
					
					
					
					
				
			
				
				
			
			
		
			
				
					0,47 [0,16;1,32]
				
			
	
	
		
			
				
				stroke (fatal and non fatal) 
				 
			
		
			
				
				4 / 237 
				
			
			
				
				13 / 243 
				
			
		
			
				
					
					
					
					
				
			
				
				
			
			
		
			
				
					0,32 [0,10;0,95]
				
			
	
	
		
			
				
				Major cardiovascular events 
				 
			
		
			
				
				37 / 237 
				
			
			
				
				39 / 243 
				
			
		
			
				
					
					
					
					
				
			
				
				
			
			
		
			
				
					0,97 [0,64;1,47]
				
			
	
	
		
		
		
		
		
			
				0
			
		
		
		
		
		
				2
		
		
		
		
		
			1.0
		
	
  
 
	 
		
	
		
		
				
					| 
						Relative risks
					 | 
				 
			
			| Endpoint | 
			Events (%) | 
			Relative Risk | 
			95% CI | 
			Endpoint definition in the trial | 
			Ref | 
			 
			
			| Studied treat. | 
			Control treat. | 
			 
					
						| 
							Cardiovascular death
						 | 
						13 / 237 (5,5%) | 
						9 / 243 (3,7%) | 
						1,48 | 
						[0,65;3,40] | 
						  | 
						11040  | 
					 
					
						| 
							myocardial  infarction (fatal and non fatal) 
						 | 
						19 / 237 (8,0%) | 
						15 / 243 (6,2%) | 
						1,30 | 
						[0,68;2,50] | 
						  | 
						11040  | 
					 
					
						| 
							stroke (fatal and non fatal) 
						 | 
						4 / 237 (1,7%) | 
						13 / 243 (5,3%) | 
						0,32 | 
						[0,10;0,95] | 
						  | 
						11040  | 
					 
					
						| 
							Major cardiovascular events 
						 | 
						37 / 237 (15,6%) | 
						39 / 243 (16,0%) | 
						0,97 | 
						[0,64;1,47] | 
						  | 
						11040  | 
					 
					
					
						| 
							All cause death
						 | 
						18 / 237 (7,6%) | 
						20 / 243 (8,2%) | 
						0,92 | 
						[0,50;1,70] | 
						  | 
						11040  | 
					 
					
						| 
							non cardiovascular death 
						 | 
						5 / 237 (2,1%) | 
						11 / 243 (4,5%) | 
						0,47 | 
						[0,16;1,32] | 
						  | 
						11040  | 
					 
					
					
						| 
							Heart failure
						 | 
						12 / 237 (5,1%) | 
						11 / 243 (4,5%) | 
						1,12 | 
						[0,50;2,49] | 
						  | 
						11040  | 
					 
					
		
			| 
			The primary endpoint (if exists) appears in blod characters
			 | 
		 
		
			| 
			Reference(s) used for data extraction: 
				
					11040: Arguedas JA, Perez MI, Wright JMTreatment blood pressure targets for hypertension.Cochrane Database Syst Rev 2009;:CD004349
				
			 | 
		 
		 
		
		
			
			| Endpoint | 
			studied treat. | 
			control treat. | 
			mean diff | 
			 
		 
	 
	
	
	
				
					| 
						Absolute risk reduction 
					 | 
				 
	
		| Endpoint | 
		Events rate | 
		Absolute risk reduction (ARR) | 
	 
	
		| Studied treat. | 
		Control treat. | 
	 
			
				| Cardiovascular death | 
				5,49% | 
				3,70% | 
				
					1,8%
				 | 
			 
			
				| myocardial  infarction (fatal and non fatal)  | 
				8,02% | 
				6,17% | 
				
					1,8%
				 | 
			 
			
				| stroke (fatal and non fatal)  | 
				1,69% | 
				5,35% | 
				
					-36,6‰
				 | 
			 
			
				| Major cardiovascular events  | 
				15,61% | 
				16,05% | 
				
					-4,4‰
				 | 
			 
			
				| All cause death | 
				7,59% | 
				8,23% | 
				
					-6,4‰
				 | 
			 
			
				| non cardiovascular death  | 
				2,11% | 
				4,53% | 
				
					-24,2‰
				 | 
			 
			
				| Heart failure | 
				5,06% | 
				4,53% | 
				
					5,4‰
				 | 
			 
	 	
	 
	
  
	
	
	
	
	
	
	
	
		 
		Reference(s)
	
	
	
			- 
				
			    Schrier RW, Estacio RO, Esler A, Mehler P. 
			    Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes..
			    Kidney Int 2002;61:1086-97
 
				
					 
					Pubmed
				 	
				|
				
					Hubmed
				
				| Fulltext
		 
		
	 	
 |